LONDON, April 27, 2012 /PRNewswire/ --
Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.
The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.
In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.
The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.
The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.
Other important topics expressed by survey respondents and that will be discussed at the event include:
Media contact: Joanna Checinska, +44(0)20-7368-9421, email@example.com - Please contact for more information or images.
Press are invited to attend this important industry forum, if you would like a complimentary press pass please email Joanna Checinska (firstname.lastname@example.org)
|SOURCE Pharma IQ|
Copyright©2010 PR Newswire.
All rights reserved